Vertex Announces U.S. FDA Approval for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations

BOSTON–(BUSINESS WIRE)–Jun. 9, 2021– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved expanded use of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include children with cystic fibrosis (CF) ages 6 through 11 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a… Read More »

Vitamin D Supplements Twice a Day Can Help Prevent Vertigo

Research has found that taking a vitamin D and calcium supplement twice daily could help reduce the chances of recurrence of vertigo. The research indicates that for individuals having benign paroxysmal positional vertigo, supplementing with vitamin D and calcium is an easy, low-risk means for preventing the recurrence of vertigo. It’s particularly effective for individuals… Read More »

PrEP for women in Europe webinar

On Tuesday 22 June at 2pm (UK time), PrEP in Europe is holding the first part of its webinar on PrEP for women in Europe. The second part will be on Tuesday 13 July. The webinar will include presentations by: Dr Sylvain Chawki, infectious disease physician and researcher in Paris. Sylvain will centre his talk… Read More »